Post hoc analysis of SUSTAIN/PIONEER trials shows semaglutide's cardiovascular protection extends across the full spectrum of risk, not just high-risk patients.
All risk levelssemaglutide's cardiovascular protection extends across the full spectrum from low to high cardiovascular risk
What the researchers found
Prior cardiovascular outcome trials showed semaglutide reduced MACE (major adverse cardiovascular events: CV death, non-fatal stroke, non-fatal MI) in high-risk patients. This post hoc analysis asked: does the benefit extend to lower-risk patients?
A cardiovascular risk prediction model was developed from LEADER trial data and validated on the semaglutide dataset (area under the curve: 0.77, indicating good predictive performance).
Key finding: semaglutide reduced both relative and absolute risk of MACE versus comparators across the entire continuum of cardiovascular risk. The relative risk reduction tended to be largest in patients with low CV risk scores. The absolute risk reduction was largest for intermediate to high risk scores (because these patients had more events to prevent).
Previous data: SUSTAIN-6 showed HR 0.74 [0.58-0.95] for injectable semaglutide vs placebo. PIONEER 6 showed HR 0.79 [0.57-1.11] for oral semaglutide vs placebo. This analysis extends those findings across the risk spectrum.
Similar patterns were seen for individual MACE components and when only placebo comparator data were included.
Why it matters
This is important for prescribing decisions. If semaglutide only protected high-risk patients, it would only be indicated for that group. Showing benefit across all risk levels supports broader use in type 2 diabetes, including patients without established cardiovascular disease.
The numbers in context
SUSTAIN-6 HR 0.74; PIONEER 6 HR 0.79; CV risk model AUC 0.77; benefit across entire risk continuum
How the study worked
Post hoc analysis combining individual patient-level data from SUSTAIN and PIONEER phase 3a clinical programs. Time-to-first-MACE analyzed by treatment assignment. CV risk model developed from independent LEADER trial data. Risk model applied to predict baseline CV risk in the semaglutide dataset, then treatment effects analyzed as a function of predicted risk.
Who was studied
Pooled SUSTAIN and PIONEER trial participants with type 2 diabetes across CV risk levels
What this study cannot tell us
Post hoc analysis, not a pre-specified trial outcome. The CV risk model was developed from LEADER (liraglutide) data and applied to semaglutide data; model transferability is assumed but not guaranteed. Individual trials were not powered for subgroup analyses by risk level. Combining data across trials with different comparators introduces heterogeneity.
How to read the evidence
Strong evidence from a post hoc analysis of large Phase 3 clinical trial data, though the post hoc nature limits certainty.
When this study was published
Published in 2020. Semaglutide's cardiovascular benefits have been further confirmed in the SELECT trial for non-diabetic obesity.
The bigger picture
If semaglutide only protected high-risk patients, it would only be prescribed for them. Showing benefit across all risk levels supports broader prescribing in type 2 diabetes, potentially preventing cardiovascular events in patients who would not have been considered high enough risk for specialized treatment.
Questions still open
- Should semaglutide be prescribed to all type 2 diabetes patients regardless of cardiovascular risk?
- Does the benefit extend to non-diabetic populations?
- What is the cost-effectiveness of broad vs targeted semaglutide prescribing?
Common questions
Does semaglutide protect against heart attacks even if I am not high-risk?
Should all diabetic patients take semaglutide?
Read the original research
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Cardiovascular diabetology, 19(1), 156
Citation
Husain, Mansoor; Bain, Stephen C; Holst, Anders Gaarsdal; Mark, Thomas; Rasmussen, Søren; Lingvay, Ildiko. (2020). Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.. Cardiovascular diabetology, 19(1), 156. https://doi.org/10.1186/s12933-020-01106-4